--- title: "Pfizer Inc. Stock Outperforms Competitors Despite Losses On The Day" type: "News" locale: "en" url: "https://longbridge.com/en/news/306020564.md" description: "Pfizer Inc. (PFE) shares fell 1.44% to $28.06 on November 18, marking its third consecutive day of losses. Despite the decline, Pfizer outperformed competitors like Johnson & Johnson and Eli Lilly, which saw steeper drops. The stock remains 10.75% below its 52-week high of $31.44. Trading volume reached 37.2 million, exceeding the 50-day average of 33.5 million." datetime: "2026-11-18T21:36:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/306020564.md) - [en](https://longbridge.com/en/news/306020564.md) - [zh-HK](https://longbridge.com/zh-HK/news/306020564.md) generator: "portal-rs" --- # Pfizer Inc. Stock Outperforms Competitors Despite Losses On The Day This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Pfizer Inc. (PFE) shed 1.44% to $28.06 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.23% to 7,323.63 and Dow Jones Industrial Average falling 1.11% to 50,198.17. This was the stock's third consecutive day of losses. Pfizer Inc. closed 10.75% short of its 52-week high of $31.44, which the company reached on November 5th. The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 2.15% to $272.70, Eli Lilly & Co. (LLY) fell 2.32% to $1,382.75, and Abbott Laboratories (ABT) fell 0.22% to $104.48. Trading volume (37.2 M) eclipsed its 50-day average volume of 33.5 M. Data source: Dow Jones Market Data, FactSet. Data compiled November 18, 2026. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 11-18-26 1636ET ### Related Stocks - [PFE.US](https://longbridge.com/en/quote/PFE.US.md) ## Related News & Research - [Pfizer inks $2.6bn autoimmune deal with China’s Starna for CAR-T therapies](https://longbridge.com/en/news/306119677.md) - [Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund](https://longbridge.com/en/news/305354338.md) - [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md) - [Anthropic PBC (ANT) Claims Claude Solved The 167 Year Old Riemann Hypothesis](https://longbridge.com/en/news/306374461.md) - [Arista Networks (ANET) Dropped, But What Is The Market Weighing Now?](https://longbridge.com/en/news/306371748.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**